Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | TSHR | P16473 | 4/20 | 0.40 |
| ▸ | USP2 | O75604 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.38 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2413249 | 0.91 | GAA (0.43) | GAAALDH1A1HTTSMN1; SMN2LMNA | |
| SCHEMBL4417723 | 0.88 | GAA (0.41) | GAAALDH1A1HTTSMN1; SMN2LMNA | |
| SCHEMBL2412129 | 0.73 | HTR6 (0.46) | ALDH1A1HTTSMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL2194154 | 0.72 | NAPRT (0.38) | ALDH1A1LMNAKDM4EKMT2AMAPT | |
| SCHEMBL2412036 | 0.71 | GAA (0.39) | GAAALDH1A1HTTSMN1; SMN2LMNA | |
| SCHEMBL14899993 | 0.71 | GPR84 (0.36) | CYP3A4MAPT | |
| SCHEMBL12417811 | 0.69 | GPR84 (0.39) | GAAHTTSMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL1830977 | 0.69 | SSTR4 (0.38) | — | |
| SCHEMBL12417843 | 0.68 | GPR84 (0.40) | CYP3A4CYP2C19MAPT | |
| SCHEMBL3477845 | 0.68 | ALOX5AP (0.36) | HTTSMN1; SMN2CYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2114917-B1 | PYRROLE COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2016-08-10 | — | — | EP | disclosed |
| US-8933105-B2 | Pyrrole compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-01-13 | — | — | US | disclosed |
| EP-2364979-A1 | Pyrrole compounds | Takeda Pharmaceutical Company Limited (JP) | 2011-09-14 | — | — | EP | disclosed |
| EP-2114917-A2 | PYRROLE COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2009-11-11 | — | — | EP | disclosed |
| US-20080262042-A1 | 1-[5-(2-Fluoropyridin-3-yl)-1-(phenylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine or a salt thereof; acid secretion inhibitor; potassium-competitive acid blocker | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-10-23 | — | — | US | disclosed |
| WO-2008108380-A2 | PYRROLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262042-A1 | 1-[5-(2-Fluoropyridin-3-yl)-1-(phenylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine or a salt thereof; acid secretion inhibitor; potassium-competitive acid blocker | REN, HRH2, ATP4A | GAA 549/4885ALDH1A1 1650/4885HTT 1563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.